In cancer, gain-of-function (GOF) JAK mutations are frequent, resulting in constitutive JAK kinase activity that can further promote the activation of other core cancer pathways, such as RAS-RAF-MAPK or PI3K-AKT-mTOR (Figure 1a). This evidence concerns the gene MTOR and cancer.